Improvement of Women's Health After Allogeneic Stem Cell Transplantation
The aim of this prospective research project is to better understand vulvovaginal cGVHD to improve care of allografted women. The expected outcomes include better knowledge of the incidence and manifestations of vulvovaginal cGVHD, risk factors, response to treatments and impact on sexual health of allotransplanted female patients. The knowledge acquired will allow transplant clinicians to make more precise recommendations for gynecological management of future allografted women.
- EligibilityCriteria: Inclusion Criteria:  All women aged 18 and over who will receive a first allogeneic HSCT (bone marrow, peripheral blood stem cells from a related, unrelated (including cord blood) or haploidentical donor) at the CIUSSS-EMTL. Recruitment will begin when the project receives ethical approval. Recruitment period will be of 2 to 3 years.  Exclusion Criteria:  Those who receive a second HSCT allograft. Those who receive an autologous transplant. Inability to give informed consent. Unable to communicate in French or English. Any other reason which, according to the investigators, makes it preferable for a patient not to participate. - HealthyVolunteers: No - Gender: Female - GenderBased: Yes - GenderDescription: All women aged 18 and over who will receive a first allogeneic HSCT - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Allotransplanted women who receive a first allogeneic stem cell transplant. - SamplingMethod: Non-Probability Sample